Agios Pharmaceuticals traded at $28.15 this Friday August 12th, increasing $2.16 or 8.31 percent since the previous trading session. Looking back, over the last four weeks, Agios Pharmaceuticals gained 24.23 percent. Over the last 12 months, its price fell by 35.95 percent. Looking ahead, we forecast Agios Pharmaceuticals to be priced at 27.36 by the end of this quarter and at 25.13 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
28.15
Daily Change
8.31%
Yearly
-35.95%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Astellas Pharma 2,034.50 20.00 0.99% 13.75%
Daiichi Sankyo 3,677.00 45.00 1.24% 60.11%
AbbVie 142.60 0.52 0.37% 22.42%
Agios Pharmaceuticals 28.15 2.16 8.31% -35.95%
Alnylam Pharmaceuticals 233.85 4.46 1.94% 18.98%
Amgen 248.39 0.04 0.02% 8.15%
Arrowhead Research 47.29 1.66 3.64% -21.86%
AstraZeneca 10,712.00 206.00 1.96% 27.13%
Bayer 54.15 2.47 4.78% 13.31%
Biogen 220.99 2.77 1.27% -35.43%
Bluebird Bio 6.72 0.41 6.50% -63.62%
BioMarin Pharmaceutical 95.07 0 0% 26.71%
Bristol-Myers Squibb 75.57 1.11 1.49% 11.94%
Epizyme 1.47 -0.02 -1.34% -72.88%
Exelixis 19.48 0.25 1.30% 6.56%
Gilead Sciences 62.96 0.51 0.82% -11.52%
GlaxoSmithKline 1,450.00 50.00 3.57% -2.80%
Immunogen 5.43 0.19 3.63% 0.93%
Incyte Corp 73.99 0.23 0.31% 0.71%
Ionis Pharmaceuticals 44.10 0.66 1.52% 11.14%
Jazz Pharmaceuticals 157.08 2.83 1.83% 10.50%
Eli Lilly 308.08 6.91 2.29% 16.60%
Merck & Co 91.02 2.09 2.35% 18.64%
Moderna Inc 171.18 -0.63 -0.37% -56.08%
Mirati Therapeutics 86.37 5.92 7.36% -38.38%
Nektar Therapeutics 5.14 0.19 3.84% -64.03%
Novartis 80.10 -0.94 -1.16% -6.82%
Novartis 85.68 0.10 0.12% -8.69%
Puma Biotechnology 3.51 -0.04 -1.13% -51.65%
Pfizer 50.11 1.82 3.77% 3.36%
Regeneron Pharmaceuticals 628.71 4.81 0.77% 0.63%
Roche Holding 315.00 4.85 1.56% -14.39%
Seattle Genetics 170.14 -3.90 -2.24% 8.76%
Sarepta Therapeutics 109.00 -0.26 -0.24% 36.35%
Vertex Pharmaceuticals 294.52 2.36 0.81% 51.53%

Indexes Price Day Year
USND 13047 267.27 2.09% -11.98%
US2000 2017 41.36 2.09% -9.29%

Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD). The Company is also developing AG-946, a clinical-stage, next-generation oral activator of pyruvate kinase R (PKR) enzymes, which is in Phase I clinical study. The mitapivat is an orally available small molecule and a potent activator of the PKR enzymes.